Amyloid β peptide as a vaccine for Alzheimer's disease involves receptor-mediated transport at the blood-brain barrier

J. F. Poduslo, G. L. Curran

Research output: Contribution to journalArticle

32 Scopus citations

Abstract

Much research is now focused on a potential vaccine for Alzheimer's disease (AD). Current studies involve administering the amyloid β peptide (Aβ) in Freund's complete adjuvant, which cannot be used in humans. Our studies show that the immune complex of Aβ is taken up by a receptor-mediated process at the blood - brain barrier (BBB). The success of immunization for AD, therefore, may be critically dependent on circulating Aβ levels which are lower in AD patients compared to AD transgenic mice. Moreover, we have found that modifying the antibody with polyamine increases its BBB permeability and may provide a better approach to passive immunization for Alzheimer's disease.

Original languageEnglish (US)
Pages (from-to)3197-3200
Number of pages4
JournalNeuroReport
Volume12
Issue number15
DOIs
StatePublished - Oct 29 2001

Keywords

  • Alzheimer's disease
  • Amyloid β peptide
  • Blood-brain barrier
  • Immune complex
  • Passive immunization
  • Permeability coefficient-surface

ASJC Scopus subject areas

  • Neuroscience(all)

Fingerprint Dive into the research topics of 'Amyloid β peptide as a vaccine for Alzheimer's disease involves receptor-mediated transport at the blood-brain barrier'. Together they form a unique fingerprint.

  • Cite this